Rhythm Pharmaceuticals Announces Upcoming Financial Control Deficiencies

Rhythm Pharmaceuticals Inc (RYTM) has released an update.

We expect to disclose a significant deficiency in our financial reporting controls in our upcoming annual report, particularly concerning IT general controls surrounding user access and program changes. These weaknesses may affect other related controls and the integrity of data from our key IT systems. While our external auditors have yet to finalize their audit, our management is working proactively with the Audit Committee and external advisors to address and rectify these issues.

For further insights into RYTM stock, check out TipRanks’ Stock Analysis page.